135 related articles for article (PubMed ID: 15712318)
41. C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II.
Prashad AS; Wang D; Subrath J; Wu B; Lin M; Zhang MY; Kagan N; Lee J; Yang X; Brennan A; Chaudhary D; Xu X; Leung L; Wang J; Boschelli DH
Bioorg Med Chem Lett; 2009 Oct; 19(19):5799-802. PubMed ID: 19703774
[TBL] [Abstract][Full Text] [Related]
42. Phorbol esters as probes for the study of protein kinase C function.
Kazanietz MG; Lorenzo PS
Methods Mol Biol; 2003; 233():423-39. PubMed ID: 12840526
[No Abstract] [Full Text] [Related]
43. Identification of a drug target motif: an anti-tumor drug NK109 interacts with a PNxxxxP.
Morohashi K; Yoshino A; Yoshimori A; Saito S; Tanuma S; Sakaguchi K; Sugawara F
Biochem Pharmacol; 2005 Jul; 70(1):37-46. PubMed ID: 15899472
[TBL] [Abstract][Full Text] [Related]
44. Study of synthetic peptides derived from the PKI55 protein, a protein kinase C modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic N-formyl tripeptide for-Met-Leu-Phe-OH.
Selvatici R; Falzarano S; Franceschetti L; Mollica A; Guerrini R; Siniscalchi A; Spisani S
FEBS J; 2008 Feb; 275(3):449-57. PubMed ID: 18167144
[TBL] [Abstract][Full Text] [Related]
45. Drug discovery process for kinase inhibitors.
Weinmann H; Metternich R
Chembiochem; 2005 Mar; 6(3):455-9. PubMed ID: 15742380
[No Abstract] [Full Text] [Related]
46. The pros and cons of targeting protein kinase C (PKC) in the management of cancer patients.
Leskow FC; Krasnapolski MA; Urtreger AJ
Curr Pharm Biotechnol; 2011 Nov; 12(11):1961-73. PubMed ID: 21470133
[TBL] [Abstract][Full Text] [Related]
47. How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance?
Bailey CP; Smith FL; Kelly E; Dewey WL; Henderson G
Trends Pharmacol Sci; 2006 Nov; 27(11):558-65. PubMed ID: 17000011
[TBL] [Abstract][Full Text] [Related]
48. SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.
Wickens P; Kluender H; Dixon J; Brennan C; Achebe F; Bacchiocchi A; Bankston D; Bierer D; Brands M; Braun D; Brown MS; Chuang CY; Dumas J; Enyedy I; Hofilena G; Hong Z; Housley T; Jones B; Khire U; Kreiman C; Kumarasinghe E; Lowinger T; Ott-Morgan R; Perkins L; Phillips B; Schoenleber R; Scott WJ; Sheeler R; Redman A; Sun X; Taylor I; Wang L; Wilhelm S; Zhang X; Zhang M; Sullivan E; Carter C; Miglarese M; Levy J
Bioorg Med Chem Lett; 2007 Aug; 17(15):4378-81. PubMed ID: 17574417
[TBL] [Abstract][Full Text] [Related]
49. Isozyme-specific inhibitors and activators of protein kinase C.
Schechtman D; Mochly-Rosen D
Methods Enzymol; 2002; 345():470-89. PubMed ID: 11665630
[TBL] [Abstract][Full Text] [Related]
50. 2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.
Nathan Tumey L; Boschelli DH; Lee J; Chaudhary D
Bioorg Med Chem Lett; 2008 Aug; 18(15):4420-3. PubMed ID: 18606543
[TBL] [Abstract][Full Text] [Related]
51. The ins and outs of protein kinase C.
Newton AC
Methods Mol Biol; 2003; 233():3-7. PubMed ID: 12840493
[No Abstract] [Full Text] [Related]
52. Protein kinase C isozymes and their selectivity towards ruboxistaurin.
Tang S; Xiao V; Wei L; Whiteside CI; Kotra LP
Proteins; 2008 Jul; 72(1):447-60. PubMed ID: 18214957
[TBL] [Abstract][Full Text] [Related]
53. Molecular cloning and expression of protein kinase C from Bombyx mori.
Uno T; Nakao A; Fujiwara Y; Katsurauma C; Nakada T; Itoh O
Arch Insect Biochem Physiol; 2006 Feb; 61(2):65-76. PubMed ID: 16416449
[TBL] [Abstract][Full Text] [Related]
54. Activation loop phosphorylation-independent kinase activity of human protein kinase C zeta.
Ranganathan S; Wang Y; Kern FG; Qu Z; Li R
Proteins; 2007 May; 67(3):709-19. PubMed ID: 17335005
[TBL] [Abstract][Full Text] [Related]
55. Discovery of potent and selective PKC-theta inhibitors.
Cywin CL; Dahmann G; Prokopowicz AS; Young ER; Magolda RL; Cardozo MG; Cogan DA; Disalvo D; Ginn JD; Kashem MA; Wolak JP; Homon CA; Farrell TM; Grbic H; Hu H; Kaplita PV; Liu LH; Spero DM; Jeanfavre DD; O'Shea KM; White DM; Woska JR; Brown ML
Bioorg Med Chem Lett; 2007 Jan; 17(1):225-30. PubMed ID: 17055721
[TBL] [Abstract][Full Text] [Related]
56. Multiple pathways control protein kinase C phosphorylation.
Parekh DB; Ziegler W; Parker PJ
EMBO J; 2000 Feb; 19(4):496-503. PubMed ID: 10675318
[No Abstract] [Full Text] [Related]
57. SRC as a potential therapeutic target in solid tumor oncology.
Gallick GE
Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218
[No Abstract] [Full Text] [Related]
58. Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics.
Chu F; Koomen JM; Kobayashi R; O'Brian CA
Cancer Res; 2005 Nov; 65(22):10478-85. PubMed ID: 16288040
[TBL] [Abstract][Full Text] [Related]
59. Functional role of the charge at the T538 residue in the control of protein kinase Ctheta.
Passalacqua M; Pedrazzi M; Sparatore B; Patrone M; Pontremoli S; Melloni E
Arch Biochem Biophys; 2009 Jan; 481(2):202-9. PubMed ID: 19056334
[TBL] [Abstract][Full Text] [Related]
60. NMDAR-nNOS generated zinc recruits PKCgamma to the HINT1-RGS17 complex bound to the C terminus of Mu-opioid receptors.
Rodríguez-Muñoz M; de la Torre-Madrid E; Sánchez-Blázquez P; Wang JB; Garzón J
Cell Signal; 2008 Oct; 20(10):1855-64. PubMed ID: 18652891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
